Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease

By T. Jafar, Christopher H. Schmid, M. Landa, I. Giatras, R. Toto, Giuseppe Remuzzi, G. Maschio, B. Brenner, A. Kamper, P. Zucchelli and 9 more. Annals of Internal Medicine, 2001

740 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Nephrology

View Paper: https://www.semanticscholar.org/paper/da0e6b6aa6ecb9a02c2b9a3a4908b3393c723869

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Giuseppe Remuzzi
2. M. Cooper
3. V. Basevi

In Endocrinology, Diabetes and Metabolism

1. M. Cooper
2. V. Basevi

In Nephrology

1. W. Mitch
2. Giuseppe Remuzzi
3. V. Basevi

Citations in the corpus

• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. (2004, methodology): “Data from several clinical trials and a meta-analysis indicate that blocking the RAS with ACE inhibitors is more renoprotective than other blood pressure–lowering strategies; the benefit coincided with a reduction in albuminuria in both nondiabetic and type 1 diabetic subjects [6, 8, 9].”